Evidence map›Paper›PMID 10678984›Full record

ArticleInfection and immunity2000

Protection against candidiasis by an immunoglobulin G3 (IgG3) monoclonal antibody specific for the same mannotriose as an IgM protective antibody.

Y Han, M H Riesselman, J E Cutler

Abstract read
In one paragraph

Article in Infection and immunity, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers.

0numbers the graph read from it
0cells of the map it votes in
55citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

55 citing papers in PubMed.

  1. Article
  2. Antifungal Innate Immunity.Advances in experimental medicine and biology · 2025
    Review
  3. Review
  4. Review
  5. Antibodies as Models and Tools to DecipherJournal of fungi (Basel, Switzerland) · 2023
    Review
  6. Article
  7. Review
  8. International journal of molecular sciences · 2021
    Article
  9. Article
  10. Monoclonal Antibodies as Tools to Combat Fungal Infections.Journal of fungi (Basel, Switzerland) · 2020
    Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Y HanDepartment of Microbiology, Montana State University, Bozeman, Montana 59717-3520, USA.
M H Riesselman
J E Cutler

Funding

PHOSPHOMANNOPROTEIN ADHESIN AS A VACCINE CANDIDATEP01AI037194 · NIAID · LA BIOMED RES INST/ HARBOR UCLA MED CTR · PI EDWARDS, JOHN E. · 1995 to 2003
$3.6M
CANDIDA ALBICANS SURFACE ANTIGENSR01AI024912 · NIAID · MONTANA STATE UNIVERSITY (BOZEMAN) · PI CUTLER, JIM E. · 1988 to 2006
$2.0M
NIAID NIH HHS P01 AI037194NIAID NIH HHS P01 AI37194NIAID NIH HHS R01 AI024912NIAID NIH HHS R01 AI24912
6 · The paper itself

Abstract

We previously reported that a liposome-mannan vaccine (L-mann) of Candida albicans induces production of mouse antibodies that protect against disseminated candidiasis and vaginal infection. Immunoglobulin M (IgM) monoclonal antibody (MAb) B6.1, specific for a C. albicans cell surface beta-1,2-mannotriose, protects mice against both infections. Another IgM MAb, termed B6, which is specific for a different cell surface mannan epitope, does not protect against disseminated candidiasis. The B6.1 epitope is displayed homogeneously over the entire cell surface, compared to a patchy distribution of the B6 epitope. To determine if protection is restricted to an IgM class of antibody, we tested an IgG antibody. MAb C3.1 was obtained from L-mann-immunized mice. By results of sodium dodecyl sulfate-polyacrylamide gel electrophoresis analysis, capture enzyme-linked immunosorbent assay, and immunodiffusion tests, MAb C3.1 is an IgG3 isotype. By epitope inhibition assays, we determined that MAb C3.1 is specific for same mannotriose as MAb B6. 1. As expected by the results of the inhibition assays, immunofluorescence microscopy showed that the C3.1 epitope is distributed on the yeast cell surface in a pattern identical to that of the B6.1 epitope. Kidney CFU and mean survival times of infected mice pretreated with MAb C3.1 indicated that the antibody enhanced resistance of mice against disseminated candidiasis. Mice in pseudoestrus that were given MAb C3.1 prior to vaginal infection developed fewer vaginal Candida CFU than control animals that received buffered saline instead of the antibody. The finding that an IgG3 antibody is protective is consistent with our hypothesis that epitope specificity and complement activation are related to the ability of an antibody to protect against candidiasis.

Indexed as

AnimalsAntibodies, MonoclonalCandidiasisEpitopesFemaleImmunoglobulin GImmunoglobulin MMiceMice, Inbred BALB CTrisaccharidesAntibodies, MonoclonalEpitopesImmunoglobulin GImmunoglobulin MmannotrioseTrisaccharides

Identifiers

PMID10678984
PMCPMC97325

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.